Atlas Trials

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Clinical trial NCT02727309 · UNKNOWN

Trial details

NCT number
NCT02727309
Sponsor
Peking University Cancer Hospital & Institute
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2015-10-01
Primary completion
2018-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.